BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar V, Mahato RI. Delivery and targeting of miRNAs for treating liver fibrosis. Pharm Res 2015;32:341-61. [PMID: 25186440 DOI: 10.1007/s11095-014-1497-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Dutta R, Kumar V, Peng Y, Evande RE, Grem JL, Mahato RI. Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice. Pharm Res 2017;34:564-78. [DOI: 10.1007/s11095-016-2081-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
2 Kumar V, Dong Y, Kumar V, Almawash S, Mahato RI. The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis. Theranostics 2019;9:7537-55. [PMID: 31695785 DOI: 10.7150/thno.38913] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
3 Kiseleva YV, Zharikov YO, Maslennikov RV, Pavlov CS, Nikolenko VN. Molecular factors associated with regression of liver fibrosis of alcoholic etiology. Terapevticheskii arkhiv 2021;93:204-8. [DOI: 10.26442/00403660.2021.02.200617] [Reference Citation Analysis]
4 Wu SM, Li TH, Yun H, Ai HW, Zhang KH. miR-140-3p Knockdown Suppresses Cell Proliferation and Fibrogenesis in Hepatic Stellate Cells via PTEN-Mediated AKT/mTOR Signaling. Yonsei Med J. 2019;60:561-569. [PMID: 31124340 DOI: 10.3349/ymj.2019.60.6.561] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
5 Peng Y, Bariwal J, Kumar V, Tan C, Mahato RI. Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment. Adv Therap 2020;3:1900136. [DOI: 10.1002/adtp.201900136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
6 Li Y, Tang R, Ma X. Epigenetics of Primary Biliary Cholangitis. Adv Exp Med Biol 2020;1253:259-83. [PMID: 32445099 DOI: 10.1007/978-981-15-3449-2_10] [Reference Citation Analysis]
7 Garza Treviño EN, González PD, Valencia Salgado CI, Martinez Garza A. Effects of pericytes and colon cancer stem cells in the tumor microenvironment. Cancer Cell Int 2019;19:173. [PMID: 31303863 DOI: 10.1186/s12935-019-0888-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
8 Xie Y, Ma H, Lian Z. Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and Implications for Autoimmunity. Clinic Rev Allerg Immunol 2016;50:390-403. [DOI: 10.1007/s12016-015-8502-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
9 El-Ahwany E, Nagy F, Zoheiry M, Shemis M, Nosseir M, Taleb HA, El Ghannam M, Atta R, Zada S. Circulating miRNAs as Predictor Markers for Activation of Hepatic Stellate Cells and Progression of HCV-Induced Liver Fibrosis. Electron Physician. 2016;8:1804-1810. [PMID: 26955452 DOI: 10.19082/1804] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
10 Kumar V, Kumar V, Luo J, Mahato RI. Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis. Mol Ther 2018;26:2798-811. [PMID: 30287074 DOI: 10.1016/j.ymthe.2018.08.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
11 Zou Y, Cai Y, Lu D, Zhou Y, Yao Q, Zhang S. MicroRNA-146a-5p attenuates liver fibrosis by suppressing profibrogenic effects of TGFβ1 and lipopolysaccharide. Cell Signal 2017;39:1-8. [PMID: 28739486 DOI: 10.1016/j.cellsig.2017.07.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
12 Kwon OS, Kim KT, Lee E, Kim M, Choi SH, Li H, Fornace AJ Jr, Cho JH, Lee YS, Lee JS, Lee YJ, Cha HJ. Induction of MiR-21 by Stereotactic Body Radiotherapy Contributes to the Pulmonary Fibrotic Response. PLoS One 2016;11:e0154942. [PMID: 27171163 DOI: 10.1371/journal.pone.0154942] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
13 Yang JJ, Tao H, Deng ZY, Lu C, Li J. Non-coding RNA-mediated epigenetic regulation of liver fibrosis. Metabolism 2015;64:1386-94. [PMID: 26362725 DOI: 10.1016/j.metabol.2015.08.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
14 Wang Y, Chen B, Xiao C, Yu J, Bu X, Jiang F, Ding W, Ge Z. Effect of miR-183-5p on Cholestatic Liver Fibrosis by Regulating Fork Head Box Protein O1 Expression. Front Physiol 2021;12:737313. [PMID: 34867446 DOI: 10.3389/fphys.2021.737313] [Reference Citation Analysis]
15 Wen M, Men R, Liu X, Yang L. Involvement of miR-30c in hepatic stellate cell activation through the repression of plasminogen activator inhibitor-1. Life Sciences 2016;155:21-8. [DOI: 10.1016/j.lfs.2016.04.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
16 Kumar V, Kumar V, Chaudhary AK, Coulter DW, McGuire T, Mahato RI. Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis. Mol Ther Nucleic Acids 2018;12:490-503. [PMID: 30195786 DOI: 10.1016/j.omtn.2018.06.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
17 Nozari E, Moradi A, Samadi M. Effect of Atorvastatin, Curcumin, and Quercetin on miR-21 and miR-122 and their correlation with TGFβ1 expression in experimental liver fibrosis. Life Sciences 2020;259:118293. [DOI: 10.1016/j.lfs.2020.118293] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Cai J, Hu M, Chen Z, Ling Z. The roles and mechanisms of hypoxia in liver fibrosis. J Transl Med 2021;19:186. [PMID: 33933107 DOI: 10.1186/s12967-021-02854-x] [Reference Citation Analysis]
19 Zhu Y, Hu Y, Cheng X, Li Q, Niu Q. Elevated miR-129-5p attenuates hepatic fibrosis through the NF-κB signaling pathway via PEG3 in a carbon CCl4 rat model. J Mol Histol 2021;52:491-501. [PMID: 33743102 DOI: 10.1007/s10735-020-09949-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Kumar V, Xin X, Ma J, Tan C, Osna N, Mahato RI. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv Rev 2021;:113888. [PMID: 34314787 DOI: 10.1016/j.addr.2021.113888] [Reference Citation Analysis]
21 Zatsepin TS, Kotelevtsev YV, Koteliansky V. Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside. Int J Nanomedicine 2016;11:3077-86. [PMID: 27462152 DOI: 10.2147/IJN.S106625] [Cited by in Crossref: 91] [Cited by in F6Publishing: 50] [Article Influence: 15.2] [Reference Citation Analysis]
22 Peng F, Tee JK, Setyawati MI, Ding X, Yeo HLA, Tan YL, Leong DT, Ho HK. Inorganic Nanomaterials as Highly Efficient Inhibitors of Cellular Hepatic Fibrosis. ACS Appl Mater Interfaces 2018;10:31938-46. [DOI: 10.1021/acsami.8b10527] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
23 Costa DF, Torchilin VP. Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy. Biomed Microdevices 2018;20:59. [PMID: 29998417 DOI: 10.1007/s10544-018-0298-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
24 Poelstra K. Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell. Curr Tissue Microenviron Rep 2020;1:13-22. [DOI: 10.1007/s43152-020-00004-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhou G, Lin W, Fang P, Lin X, Zhuge L, Hu Z, Jin L. MiR-10a improves hepatic fibrosis by regulating the TGFβl/Smads signal transduction pathway. Exp Ther Med 2016;12:1719-22. [PMID: 27602086 DOI: 10.3892/etm.2016.3542] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
26 Shrestha N, Chand L, Han MK, Lee SO, Kim CY, Jeong YJ. Glutamine inhibits CCl4 induced liver fibrosis in mice and TGF-β1 mediated epithelial-mesenchymal transition in mouse hepatocytes. Food Chem Toxicol 2016;93:129-37. [PMID: 27137983 DOI: 10.1016/j.fct.2016.04.024] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
27 Su Q, Kumar V, Sud N, Mahato RI. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev. 2018;129:54-63. [PMID: 29391222 DOI: 10.1016/j.addr.2018.01.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 12.8] [Reference Citation Analysis]
28 Bao S, Huang S, Liu Y, Hu Y, Wang W, Ji M, Li H, Zhang NX, Song C, Duan S. Gold nanocages with dual modality for image-guided therapeutics. Nanoscale 2017;9:7284-96. [DOI: 10.1039/c7nr01350g] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]